Literature DB >> 10074202

Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity.

L C de la Carrière1, S Paulous, F Clavel, F Mammano.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) variants resistant to protease inhibitors often display a reduced replicative capacity as a result of an impairment of protease function. Such fitness-impaired viruses display Gag precursor maturation defects. Here, we report that some protease inhibitor-resistant viruses also display abnormalities in the processing of reverse transcriptase (RT) by the protease. In three recombinant viruses carrying resistant protease sequences from patient plasma, we observed a marked decrease in the amount of mature RT subunits and of particle-associated RT activity compared to their parental pretherapy counterparts. We investigated the possibility that a decrease in the amount of particle-associated mature RT could affect the sensitivity of the corresponding virus to RT inhibitors. We observed a twofold increase of sensitivity to zidovudine (AZT) when a virus which carried AZT mutations was processed by a resistant protease. Interestingly, the presence of AZT-resistance mutations partially rescued the replication defect associated with the mutated protease. The interplay between resistance to protease inhibitors and to RT inhibitors described here may be relevant to the therapeutic control of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10074202      PMCID: PMC104112     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  HIV-1 reverse transcription. A termination step at the center of the genome.

Authors:  P Charneau; G Mirambeau; P Roux; S Paulous; H Buc; F Clavel
Journal:  J Mol Biol       Date:  1994-09-02       Impact factor: 5.469

2.  Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.

Authors:  M Markowitz; H Mo; D J Kempf; D W Norbeck; T N Bhat; J W Erickson; D D Ho
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

3.  The not-so-great escape.

Authors:  J W Erickson
Journal:  Nat Struct Biol       Date:  1995-07

4.  Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.

Authors:  D D Ho; T Toyoshima; H Mo; D J Kempf; D Norbeck; C M Chen; N E Wideburg; S K Burt; J W Erickson; M K Singh
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

5.  Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.

Authors:  B A Larder; S D Kemp; P R Harrigan
Journal:  Science       Date:  1995-08-04       Impact factor: 47.728

6.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Authors:  J H Condra; W A Schleif; O M Blahy; L J Gabryelski; D J Graham; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

7.  Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine.

Authors:  M F Kavlick; T Shirasaka; E Kojima; J M Pluda; F Hui; R Yarchoan; H Mitsuya
Journal:  Antiviral Res       Date:  1995-10       Impact factor: 5.970

8.  Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients.

Authors:  F Mammano; C Petit; F Clavel
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

9.  Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors.

Authors:  D L Winslow; S Stack; R King; H Scarnati; A Bincsik; M J Otto
Journal:  AIDS Res Hum Retroviruses       Date:  1995-01       Impact factor: 2.205

10.  Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug.

Authors:  A M Borman; S Paulous; F Clavel
Journal:  J Gen Virol       Date:  1996-03       Impact factor: 3.891

View more
  16 in total

1.  Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.

Authors:  H C Côté; Z L Brumme; P R Harrigan
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Viral evolution in response to the broad-based retroviral protease inhibitor TL-3.

Authors:  B Bühler; Y C Lin; G Morris; A J Olson; C H Wong; D D Richman; J H Elder; B E Torbett
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 3.  The choreography of HIV-1 proteolytic processing and virion assembly.

Authors:  Sook-Kyung Lee; Marc Potempa; Ronald Swanstrom
Journal:  J Biol Chem       Date:  2012-10-05       Impact factor: 5.157

4.  Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.

Authors:  G Bleiber; M Munoz; A Ciuffi; P Meylan; A Telenti
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.

Authors:  F Mammano; V Trouplin; V Zennou; F Clavel
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity.

Authors:  Gavin J Henderson; Sook-Kyung Lee; David M Irlbeck; Janera Harris; Melissa Kline; Elizabeth Pollom; Neil Parkin; Ronald Swanstrom
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

7.  Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir.

Authors:  Wolfgang Resch; Neil Parkin; Terri Watkins; Janera Harris; Ronald Swanstrom
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

8.  Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.

Authors:  Wolfgang Resch; Rainer Ziermann; Neil Parkin; Andrea Gamarnik; Ronald Swanstrom
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid.

Authors:  Deborah J Lee; W E Robinson
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

10.  Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1.

Authors:  Lay Myint; Masakazu Matsuda; Zene Matsuda; Yoshiyuki Yokomaku; Tomoko Chiba; Aiko Okano; Kaneo Yamada; Wataru Sugiura
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.